BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Euronext Paris 04:39:56 07/06/2024 pm IST | ||
| 2.97 EUR | +0.34% |
|
| Current month | +14.29% | ||
| 1 month | +88.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 2.97 | +0.34% |
| 06/24/06 | 2.96 | +1.72% |
| 05/24/05 | 2.91 | +3.93% |
| 04/24/04 | 2.8 | -2.78% |
| 03/24/03 | 2.88 | +11.20% |
Real-time Euronext Paris
Last update June 07, 2024 at 04:39 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 7A86S | |
| ISIN | DE000SU78318 |
| Date issued | 13/02/2024 |
| Strike | 680.5 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 1.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.11 € |
|---|---|
| Lowest since issue | 0.95 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
- Stock Market
- Certificates
- 7A86S Certificat
